A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Alcon

Status and phase: Completed; Phase 2

Conditions: Open-angle Glaucoma; Ocular Hypertension

Treatments: Other: AL-37807 Vehicle; Drug: Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%; Drug: AL-37807 Ophthalmic Suspension, 1.0%; Drug: Latanoprost, 0.005% (Xalatan)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00287521

C-04-68

Details and patient eligibility

About

The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.

Enrollment: 87 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed with open-angle glaucoma (with ot without pseudoexfoliation or pigment dispersion component) or ocular hypertension
• Other protocol-defined inclusion criteria may apply.

Exclusion criteria

• Under 18
• Other protocol-defined exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

87 participants in 4 patient groups, including a placebo group

AL-37807 Suspension

Experimental group

Treatment:

Drug: AL-37807 Ophthalmic Suspension, 1.0%

Xalatan

Active Comparator group

Treatment:

Drug: Latanoprost, 0.005% (Xalatan)

AL-37807 Vehicle

Placebo Comparator group

Treatment:

Other: AL-37807 Vehicle

Timolol Maleate

Experimental group

Treatment:

Drug: Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%